Harnessing Resealed Erythrocytes for Advanced Drug Delivery Applications
Abstract
The use of resealed erythrocytes as drug delivery vehicles has emerged as a promising approach in advanced therapeutic applications. These biocompatible carriers offer unique advantages, including prolonged circulation time, reduced immunogenicity, and the ability to encapsulate a wide range of therapeutic agents, from small molecules to macromolecules. This study explores the potential of resealed erythrocytes in drug delivery, focusing on the techniques used for their preparation, the types of drugs that can be encapsulated, and the mechanisms by which these cells release their cargo in a controlled manner. Additionally, the challenges and limitations associated with this technology are critically examined, along with the current state of clinical research and potential future applications. By harnessing the natural properties of erythrocytes, this innovative drug delivery system holds significant promise for enhancing the efficacy and safety of treatments for a variety of diseases, paving the way for more targeted and personalized therapeutic strategies.
Keywords
Resealed erythrocytes, drug delivery, targeted therapy, encapsulation, biocompatible carriersHow to Cite
References
Vyas SP and Khar RK., Resealed Erythrocytes in Targeted and Controlled Drug Delivery: novel Carrier Systems, CBS Publishers and Distributors, India, 2002;87–416.
Shashank Shah., Novel Drug Delivery Carrier: Resealed Erythrocytes, International Journal of Pharma and BioSciences 2011; 2:394-406.
Tortora GJ., Grabowski SR., The Cardiovascular System: The Blood In: Principles of Anatomy and Physiology, 7th ed. New York: Harper Collins College Publishers,1993;566- 590.
Guyton AC., Hall JE., Textbook of Medical Physiology Philadelphia: W.B. Saunders, 1996;425-433.
Diem K., Lentner C., Documenta G., Scientific Tables, Geigy Pharmaceuticals (Ciba-Geigy Ltd.) 7th ed, 1975;617-618.
Spector WS., Handbook of Biological Data Philadelphia: W. B. Saunders, 1956;52 & 70.
Kawai R., Lemaire M., Steimer JL., Bruelisauer A., Niederberger W., Rowland M,, Physiologically based pharmacokinetic study on a cyclosporine derivative SDZ IMM 125, Journal of Pharmacokinetics and Biopharmaceutics 1994;22:5:1994:327–365.
Steinberg MH., Pathobiology of the Human Erythrocyte and Its Haemoglobins, In: Hoffman R, Benz E, Shattil S, Furie B, Cohen H, editors. “Hematology: basic principles and practice”, 4th ed., Philadelphia: Churchill Livingstone; 2005;442-456.
Beutler E., Lichtman MA., Coller BS., Kipos TJ., Williams Hematology, New York: McGraw Hill Inc; 1995;349–363.
Tortora GJ., Grabowski SR., The Cardiovascular System: The Blood, Principles of Anatomy and Physiology, 1993;566–590.
Shyama SK., Rathore KS., Keshri R., Resealed Erythrocytes: Potential Carrier for delivery of Drugs, International Journal of Pharmaceutical Eruditon 2015;4:4:34-47.
Ihler GM., Erythrocyte Carriers, PharmacolTher 1983;20:151–169.
Copyright (c) 2024 Vaisakha Sharma (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
